MAZE THERAPEUTICS INC (MAZE) competitors & alternatives
Health Care · NASDAQ
MAZE THERAPEUTICS INC (MAZE)'s top competitors and alternatives — its most similar public companies — include INHIBRX BIOSCIENCES INC (INBX), PALVELLA THERAPEUTICS INC (PVLA), VERADERMICS INC (MANE), RAPPORT THERAPEUTICS INC (RAPP), NEUMORA THERAPEUTICS INC (NMRA), Tenaya Therapeutics, Inc. (TNYA), GENERATE BIOMEDICINES INC (GENB), NURIX THERAPEUTICS INC (NRIX), ALTO NEUROSCIENCE INC (ANRO), RELAY THERAPEUTICS INC (RLAY), ANAVEX LIFE SCIENCES CORP (AVXL) and TYRA BIOSCIENCES INC (TYRA). These are MAZE THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top MAZE competitors & alternatives
-
INHIBRX BIOSCIENCES INCINBXHealth Care
A clinical-stage biopharma company leveraging proprietary protein engineering to develop next-generation biologic therapeutics for hard-to-treat solid tumors.
$85.92 (as of 2026-07-22) · market cap $1.3B
-
PALVELLA THERAPEUTICS INCPVLAHealth Care
A clinical-stage biopharmaceutical company developing proprietary therapeutics for rare skin diseases and vascular malformations following the merger of Pieris…
$142.18 (as of 2026-07-22) · market cap $2.0B
-
VERADERMICS INCMANEHealth Care
VeraDermics is a clinical-stage biotech developing an oral, extended-release minoxidil formulation (VDPHL01) to address the 80 million Americans with pattern…
$109.85 (as of 2026-07-22) · market cap $4.5B
-
RAPPORT THERAPEUTICS INCRAPPHealth Care
Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex…
$41.33 (as of 2026-07-22) · market cap $2.1B
-
NEUMORA THERAPEUTICS INCNMRAHealth Care
Neumora Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for psychiatric and neurodegenerative brain disorders.
$1.54 (as of 2026-07-22) · market cap $298M
-
Tenaya Therapeutics, Inc.TNYAHealth Care
Tenaya Therapeutics is a clinical-stage biopharmaceutical company leveraging gene therapy and small molecule platforms to develop curative, precision-medicine…
$0.79 (as of 2026-07-22) · market cap $171M
-
GENERATE BIOMEDICINES INCGENBHealth Care
Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein…
$13.90 (as of 2026-07-22) · market cap $1.8B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
ALTO NEUROSCIENCE INCANROHealth Care
Alto Neuroscience is a clinical-stage biotech developing precision medicines for neuropsychiatric conditions by using biomarkers to match patients to targeted…
$27.23 (as of 2026-07-22) · market cap $1.0B
-
RELAY THERAPEUTICS INCRLAYHealth Care
A precision medicine company using computational drug discovery to target protein motion and advance a pipeline of novel small molecule therapeutics.
$19.27 (as of 2026-07-22) · market cap $4.2B
-
ANAVEX LIFE SCIENCES CORPAVXLHealth Care
Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple…
$2.55 (as of 2026-07-22) · market cap $234M
-
TYRA BIOSCIENCES INCTYRAHealth Care
Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly…
$30.59 (as of 2026-07-22) · market cap $1.8B
Not quite? Describe exactly what you want →
Peers are MAZE THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: MAZE THERAPEUTICS INC (MAZE).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.